Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma
Acromegaly Due to Pituitary Adenoma
OTHER: GIP-A|OTHER: Placebo
Growth hormone levels, Plasma growth hormone area under the curve (AUC), 240 min
Glucose levels, Plasma glucose AUC, 240 min|GIP levels, Plasma GIP AUC, 240 min|Insulin levels, Serum insulin AUC, 240 min|C-peptide levels, Serum C-peptide AUC, 240 min|Insulin-like growth factor-1 (IGF-1) levels, Plasma IGF-1 AUC, 240 min|Free fatty acids (FFA) levels, serum FFA AUC, 240 min|Glucagon levels, plasma glucagon AUC, 240 min|Ghrelin levels, plasma ghrelin AUC, 240 min|GLP-1 levels, Plasma GLP-1 AUC, 240 min|GLP-2 levels, Plasma GLP-2 AUC, 240 min|Plasma cholesterol, Plasma cholesterol AUC, 240 min|Plasma triglyceride, Plasma triglyceride AUC, 240 min|Plasma TSH, Plasma TSH AUC, 240 min|Plasma prolactin, Plasma prolactin AUC, 240 min
Aim: To determine the importance of the GIP system in patients with acromegaly who has paradoxical growth hormone secretion during an oral glucose tolerance test (OGTT) using a GIP antagonist (GIP-A).

Thirty participants (age 18-75 years) with normal kidney and liver parameters and hemoglobin levels will be included in a placebo-controlled cross-over study. The study consists of two study days with concomitant infusions of A) GIP-A or B) saline (placebo).

A paradoxical growth hormone secretion to an OGTT is here defined as an increase in plasma growth hormone levels of â‰¥30% from baseline based on a mean value of the definitions in the literature.

Regazzo et al. (2017) European Journal of Endocrinology 176, 543-553 Mukai et al. (2018) The Journal of Clinical Endocrinology and Metabolism 104(5), 1637-1644 Hage et al. (2019) The Journal of Clinical Endocrinology and Metabolism 104(5), 1777-1787 Scaroni et al. (2019) J Clin Endocrinol Metab 104(3), 856-862